Educational content only. Not medical advice. The content creators are not doctors or medical professionals. Consult your healthcare provider before taking any action.
Quick answer
MK-677 is an oral ghrelin-receptor agonist that raises GH and IGF-1 but worsened insulin sensitivity in trials; CJC-1295/Ipamorelin is an injectable GHRH-analog-plus-GHRP combination that preserves GH pulsatility. Neither is FDA-approved, both are WADA-banned, and no head-to-head human trial compares them.
MK-677 (ibutamoren) is an oral, non-peptide ghrelin-receptor agonist studied for raising growth hormone (GH) and IGF-1; CJC-1295/Ipamorelin is an injectable GHRH-analog-plus-GHRP combination studied for the same axis. They differ in route, half-life, side-effect profile, and 2026 regulatory status. This guide compares both for educational purposes.
MK-677 vs CJC-1295/Ipamorelin at a glance
| Attribute | MK-677 (Ibutamoren) | CJC-1295 / Ipamorelin |
|---|---|---|
| Class | Oral non-peptide ghrelin-receptor (GHS-R1a) agonist | Injectable GHRH analog (CJC-1295) + selective GHRP (Ipamorelin) |
| How it raises GH | Mimics ghrelin; amplifies GH pulses and basal GH | CJC-1295 sustains GHRH signaling; Ipamorelin triggers a GH pulse |
| Route | Oral (tablet/liquid) | Subcutaneous injection |
| Half-life | ~4–6 hours (once-daily, in research) | Ipamorelin ~2 hours; CJC-1295 no-DAC short; CJC-1295 with DAC ~6–8 days (Teichman 2006) |
| Commonly cited research dose | 25 mg/day in published human trials | Research literature varies; combination dosing not established in pivotal human trials |
| Typical cited cycle | Studied up to 12–24 months in trials | No standardized human protocol |
| Best-studied effect | Raises IGF-1 and fat-free mass in older adults (Nass 2008) | Sustained GH/IGF-1 elevation with preserved pulsatility (Ionescu 2006) |
| Notable safety signal | Increased fasting glucose, reduced insulin sensitivity; CHF signal in a hip-fracture trial (Adunsky 2011) | Injection-site reactions; long-term human safety data limited |
| FDA status (2026) | Not approved; investigational research chemical | Not approved; removed from 503A Category 2 in 2024; PCAC declined inclusion |
| WADA status | Prohibited (S2) at all times | Prohibited (S2) at all times |
What is the core difference between MK-677 and CJC-1295/Ipamorelin?
Both approaches aim to raise endogenous growth hormone and downstream IGF-1, but they act on different receptors and arrive by different routes. Understanding the distinction is the foundation of any meaningful comparison.
MK-677 (ibutamoren) is an orally active, non-peptide compound that mimics the hormone ghrelin. It binds the growth hormone secretagogue receptor (GHS-R1a) in the pituitary and hypothalamus, amplifying the body's own GH pulses and sustaining elevated IGF-1 for up to 24 hours after a single dose. Because it is a small molecule rather than a peptide, it survives digestion and is taken by mouth — the feature that distinguishes it most sharply from injectable alternatives.
CJC-1295/Ipamorelin is a two-peptide combination delivered by subcutaneous injection. CJC-1295 is a long-acting analog of growth-hormone-releasing hormone (GHRH); in healthy adults, a single dose produced dose-dependent increases in GH (2- to 10-fold) and IGF-1 (1.5- to 3-fold), with an estimated half-life of 5.8–8.1 days for the DAC-conjugated form (Teichman et al., 2006, J Clin Endocrinol Metab). Ipamorelin is a selective GHRP — a pentapeptide that activates the same GHS-R1a receptor as ghrelin but, unlike older secretagogues, did not meaningfully raise ACTH, cortisol, or prolactin in animal studies (Raun et al., 1998, Eur J Endocrinol). Combining a GHRH analog with a GHRP is thought to be synergistic because the two pathways reinforce each other at the receptor level (Sigalos & Pastuszak, 2018, Sex Med Rev).
In short: MK-677 is one oral molecule mimicking ghrelin; CJC-1295/Ipamorelin is two injectable peptides hitting two complementary GH pathways. Learn more in our growth hormone peptides explainer.
How does MK-677 work, and what does the human evidence show?
MK-677 occupies the ghrelin receptor and increases both the amplitude of natural GH pulses and basal GH output, raising 24-hour GH and IGF-1 levels. Its oral bioavailability is its defining advantage; its metabolic side-effect profile is its defining limitation.
The strongest human evidence comes from a 2-year, double-blind, randomized, placebo-controlled trial in 65 healthy older adults aged 60–81. Daily 25 mg MK-677 restored GH and IGF-1 to levels typical of healthy young adults and increased fat-free mass relative to placebo, without serious adverse effects attributed to the drug across the cohort (Nass et al., 2008, Ann Intern Med). This trial (registered as NCT00474279 on ClinicalTrials.gov) remains the most-cited efficacy reference for the compound.
However, the same body of evidence carries a clear safety caution. In the Nass trial, fasting blood glucose rose and insulin sensitivity declined in the MK-677 group. A separate Phase IIb trial in 123 elderly patients recovering from hip fracture, using the same 25 mg/day dose, was terminated early: congestive heart failure occurred in 4 of 62 MK-677 patients (6.5%) versus 1 of 61 on placebo (1.7%), and the authors concluded the compound had an unfavorable safety profile in that vulnerable population (Adunsky et al., 2011, Arch Gerontol Geriatr). Research protocols in the literature commonly cite 25 mg once daily, but dosing should never be self-directed; consult your healthcare provider before considering any growth-hormone-axis compound. See our MK-677 educational guide for a deeper look.
How does CJC-1295/Ipamorelin work, and what does the human evidence show?
CJC-1295/Ipamorelin raises GH and IGF-1 by combining sustained GHRH signaling with a discrete GHRP-driven pulse. The combination is popular in research and clinic settings precisely because the two peptides target complementary control points of the GH axis.
CJC-1295's defining feature is duration. The DAC (drug-affinity-complex) version binds albumin, extending its half-life to roughly 6–8 days, which produced GH elevations lasting six days or more and IGF-1 elevations of 9–11 days after a single injection in healthy adults (Teichman et al., 2006, J Clin Endocrinol Metab). Critically, a follow-up study showed that continuous stimulation by CJC-1295 preserved the body's natural pulsatile GH rhythm rather than flattening it — basal GH rose 7.5-fold while pulse frequency stayed intact (Ionescu & Frohman, 2006, J Clin Endocrinol Metab). Preserving pulsatility matters because it keeps GH under physiologic negative feedback, a theoretical safety advantage over exogenous GH injection (Sigalos & Pastuszak, 2018, Sex Med Rev).
Ipamorelin contributes a clean, selective GH pulse. In the original characterization, ipamorelin released GH with high potency yet, unlike GHRP-6 and other early secretagogues, did not significantly elevate cortisol or prolactin — a selectivity that underpins its research appeal (Raun et al., 1998, Eur J Endocrinol). The important caveat: while each peptide has individual human or animal data, the specific CJC-1295-plus-Ipamorelin combination has not been validated in large pivotal human trials, so combination "protocols" circulating online are not supported by FDA-grade evidence. Our CJC-1295/Ipamorelin educational guide covers the nuances.
When might someone study MK-677 vs CJC-1295/Ipamorelin?
There is no FDA-approved use for either approach, so the framing below is strictly about how the two are discussed in research and educational contexts — not a recommendation to use them. Consult your healthcare provider before starting any peptide protocol.
| Scenario | Commonly discussed lean | Why |
|---|---|---|
| Preference for oral, needle-free administration | MK-677 | Only oral option of the two; no injections |
| Concern about insulin sensitivity / glucose | CJC-1295/Ipamorelin | MK-677 consistently raised fasting glucose and lowered insulin sensitivity (Nass 2008) |
| Pre-existing cardiac vulnerability | Neither without a provider | CHF signal seen with MK-677 in frail elderly (Adunsky 2011); injectables also unstudied long-term |
| Desire to preserve natural GH pulsatility | CJC-1295/Ipamorelin | Pulsatile rhythm preserved under CJC-1295 (Ionescu 2006) |
| Appetite stimulation is undesirable | CJC-1295/Ipamorelin | Ghrelin-mimetic MK-677 commonly increases hunger |
| Athletes subject to drug testing | Neither | Both prohibited at all times by WADA (S2) |
The honest takeaway: neither is established as superior for any health outcome, because head-to-head human trials comparing the two do not exist. Any "lean" above reflects mechanism and side-effect logic, not direct comparative evidence. Goal-oriented readers may also find our peptides for muscle growth hub and peptides for longevity hub useful context.
How do the side effects of MK-677 and CJC-1295/Ipamorelin compare?
Both raise IGF-1, which carries shared theoretical concerns (water retention, joint discomfort, and the broad caution that chronically elevated IGF-1 is biologically active tissue-growth signaling). Their distinct profiles diverge mainly on metabolism and route.
| Side effect / risk | MK-677 (Ibutamoren) | CJC-1295 / Ipamorelin |
|---|---|---|
| Increased appetite | Common (ghrelin mimetic) | Mild/variable (Ipamorelin is GHS-R agonist) |
| Fluid retention / edema | Reported in trials | Reported anecdotally; limited trial data |
| Fasting glucose / insulin resistance | Documented increase (Nass 2008) | Less emphasized in literature; data limited |
| Joint pain / carpal-tunnel-type symptoms | Reported | Reported anecdotally |
| Congestive heart failure signal | Seen in frail elderly hip-fracture trial (Adunsky 2011) | Not reported in available human studies |
| Injection-site reactions | None (oral) | Possible (subcutaneous route) |
| Cortisol / prolactin elevation | Minimal | Minimal for Ipamorelin (selective; Raun 1998) |
| Long-term cancer/mortality data | Not established | Not established |
Two safety themes deserve emphasis. First, the metabolic signal with MK-677 is consistent and clinically meaningful — elevated fasting glucose and reduced insulin sensitivity persisted across the 2-year Nass trial, which is directly relevant to anyone with prediabetes or metabolic risk. Second, every reviewer of this class flags the same gap: long-term safety, including cancer incidence and mortality with sustained IGF-1 elevation, has not been adequately studied for any GH secretagogue (Sigalos & Pastuszak, 2018, Sex Med Rev). These are research compounds, not validated therapies. Consult your healthcare provider before starting any peptide protocol, and report any chest symptoms, swelling, or blood-sugar changes promptly.
What do MK-677 and CJC-1295/Ipamorelin cost, and how accessible are they?
Neither compound is an FDA-approved prescription product, so there is no standardized retail price, no insurance coverage, and no quality guarantee from a regulated supply chain. Pricing below reflects the gray and research-chemical markets and is provided for educational orientation only.
MK-677 is generally sold as a research chemical (oral tablets or liquid) and is typically the lower monthly cost of the two because it requires no injection supplies and a single compound. CJC-1295/Ipamorelin is usually sold as a lyophilized injectable blend requiring reconstitution, bacteriostatic water, and syringes, which raises the practical cost and complexity. In NYC, some longevity and wellness clinics have historically offered injectable GH-secretagogue peptides through compounding pharmacies, but that pathway narrowed sharply in 2024–2026 (see the regulatory section below).
The accessibility caveat is significant: research-chemical and gray-market products are not tested for identity, purity, or sterility, and analyses of the sector have repeatedly found mislabeled or contaminated material. There is no way to verify that an unregulated vial contains what the label claims. Our FDA 503A peptide status guide explains why legitimate compounded supply has contracted. Legal status varies by jurisdiction; consult a lawyer for binding advice.
Can MK-677 and CJC-1295/Ipamorelin be stacked together?
Mechanistically, MK-677 and CJC-1295/Ipamorelin overlap and partly duplicate each other, so combining all three is more redundant than synergistic — and it compounds the side-effect and safety unknowns. This is discussed in communities but is not supported by clinical evidence.
The redundancy is in the receptors. MK-677 and Ipamorelin both act as agonists at GHS-R1a (the ghrelin receptor). Stacking two ghrelin-pathway agonists adds little incremental signal at that receptor while potentially intensifying shared effects like appetite increase and IGF-1 elevation. The established synergy in the literature is between a GHRH analog and a GHRP — that is exactly what CJC-1295 (GHRH analog) plus Ipamorelin (GHRP) already provides; the two pathways are independent and reinforce one another at the receptor (Sigalos & Pastuszak, 2018, Sex Med Rev). Adding MK-677 on top mainly stacks a second GHRP-like agent.
More importantly, no human trial has evaluated the safety of combining oral MK-677 with injectable CJC-1295/Ipamorelin. The MK-677 metabolic signal (higher glucose, lower insulin sensitivity) and the cardiac signal seen in frail patients (Adunsky et al., 2011) do not disappear when a peptide is added — they may stack. Educational content cannot endorse a combination that has never been studied for safety. Consult your healthcare provider before starting any peptide protocol.
What is the 2026 FDA and WADA status of MK-677 vs CJC-1295/Ipamorelin?
Neither MK-677 nor CJC-1295/Ipamorelin is FDA-approved, and both are prohibited in sport by WADA at all times. Their compounding-law status diverged in 2024–2026, and the regulatory picture is actively shifting.
For CJC-1295 and ipamorelin: in September 2023 the FDA placed a group of peptide bulk drug substances into Category 2 of the interim 503A bulks list, citing significant safety concerns. On September 20, 2024, the FDA announced removal of five substances — including CJC-1295 and ipamorelin acetate — from Category 2 after the nominators withdrew their nominations, effective September 27, 2024 (FDA, 2024). Crucially, removal from Category 2 did not mean approval: these substances were never placed on Category 1, so 503A pharmacies still lack a lawful basis to compound them. At the FDA's October 2024 PCAC meeting, the agency's own analysis recommended that ipamorelin and ibutamoren mesylate not be added to the 503A bulks list, and the committee did not vote them onto it.
The picture sharpened in 2026. On April 16, 2026, the FDA published a Federal Register notice scheduling a Pharmacy Compounding Advisory Committee (PCAC) meeting for July 23–24, 2026 to review another tranche of peptides (including BPC-157, TB-500, KPV, Epitalon, and others) — but CJC-1295, ipamorelin, and MK-677 were not among the substances under fresh consideration, leaving them outside any lawful compounding pathway (FDA Law Blog, April 2026). [VERIFY: that none of MK-677/CJC-1295/Ipamorelin appear on any final PCAC July 2026 agenda revision]. MK-677, as a non-peptide small molecule, sits outside the peptide-compounding framework entirely and is sold only as an unapproved research chemical.
On the sport side, both are unambiguously banned. WADA's Prohibited List classifies GHRH analogs (including CJC-1295) and growth-hormone secretagogues/mimetics (including ibutamoren/MK-677 and ipamorelin) under category S2, prohibited at all times, in and out of competition (WADA Prohibited List, 2026). A single dose of modified CJC-1295 can remain detectable for weeks. Legal status varies by jurisdiction; consult a lawyer for binding advice, and consult your healthcare provider before considering any of these compounds.
Frequently asked questions
Q: Is MK-677 better than CJC-1295/Ipamorelin? A: There is no evidence that either is "better," because no head-to-head human trial has compared them. They raise GH and IGF-1 by different mechanisms with different trade-offs: MK-677 is oral and convenient but consistently raised fasting glucose and reduced insulin sensitivity in a 2-year trial (Nass et al., 2008), while CJC-1295/Ipamorelin requires injections but appears to preserve natural GH pulsatility (Ionescu & Frohman, 2006). Neither is FDA-approved. The "better" choice is a medical decision; discuss it with a licensed healthcare provider.
Q: Which raises IGF-1 more, MK-677 or CJC-1295? A: Both reliably raise IGF-1 in human studies. MK-677 at 25 mg/day restored IGF-1 to young-adult levels over months (Nass et al., 2008). A single dose of CJC-1295 raised IGF-1 1.5- to 3-fold for 9–11 days, and repeated dosing kept IGF-1 above baseline for up to 28 days (Teichman et al., 2006). Because the studies used different designs, doses, and timeframes, the magnitudes are not directly comparable. Sustained high IGF-1 carries unstudied long-term risks.
Q: Does MK-677 cause more side effects than CJC-1295/Ipamorelin? A: MK-677 has a clearer documented metabolic downside — increased fasting glucose and reduced insulin sensitivity across a 2-year trial — plus a congestive-heart-failure signal in a hip-fracture trial that stopped early (Adunsky et al., 2011). CJC-1295/Ipamorelin's main route-specific issue is injection-site reactions, and Ipamorelin is notably selective, sparing cortisol and prolactin (Raun et al., 1998). However, long-term human safety data are limited for both, so the comparison is incomplete. Consult your healthcare provider.
Q: Can you take MK-677 and CJC-1295/Ipamorelin at the same time? A: This combination is discussed online but has never been tested for safety in any human trial. Mechanistically it is partly redundant, because MK-677 and Ipamorelin both activate the same ghrelin (GHS-R1a) receptor, so stacking them adds limited incremental benefit while potentially compounding side effects like appetite and IGF-1 elevation. Peptides.NYC does not endorse unstudied combinations. Consult your healthcare provider before starting any peptide protocol.
Q: Are MK-677 and CJC-1295/Ipamorelin legal in 2026? A: Neither is FDA-approved. CJC-1295 and ipamorelin were removed from the FDA's 503A Category 2 list in September 2024 but were never added to Category 1, so they have no lawful compounding pathway, and the FDA recommended against including ipamorelin and ibutamoren on the 503A bulks list. MK-677 is sold only as an unapproved research chemical. Both are banned in sport by WADA (S2). Legal status varies by jurisdiction; consult a lawyer.
Q: Will MK-677 or CJC-1295/Ipamorelin show up on a drug test? A: Yes, for athletes tested under WADA rules. Both are classified under WADA category S2 (peptide hormones, growth factors, and mimetics) and prohibited at all times. WADA-accredited labs screen for them by mass spectrometry, and modified CJC-1295 can remain detectable for 28 days or more after a single dose. Standard employment drug panels typically do not test for these compounds.
Q: Do MK-677 or CJC-1295/Ipamorelin build muscle? A: In older adults, 25 mg/day MK-677 increased fat-free mass versus placebo, though it did not improve muscle strength in that trial (Nass et al., 2008). CJC-1295/Ipamorelin raises GH and IGF-1, which are anabolic signals, but no controlled human trial has shown the combination builds measurable muscle. Raising the GH axis is not the same as proven, safe muscle gain. Consult your healthcare provider before pursuing any protocol.
References
- Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611. PMID: 18981485. https://pubmed.ncbi.nlm.nih.gov/18981485/
- Adunsky A, Chandler J, Heyden N, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011;53(2):183-189. PMID: 21067829. https://pubmed.ncbi.nlm.nih.gov/21067829/
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID: 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28400207. PMC5632578. https://pmc.ncbi.nlm.nih.gov/articles/PMC5632578/
- U.S. National Library of Medicine. Effects of an oral GH secretagogue (MK-677) on body composition and functional ability of older adults. ClinicalTrials.gov Identifier: NCT00474279. https://clinicaltrials.gov/study/NCT00474279
- U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A — Category 2 updates (CJC-1295, ipamorelin acetate, and others removed September 2024). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-fdcact
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting — Federal Register notice (peptide bulk drug substances), April 16, 2026; meeting July 23–24, 2026. https://www.fda.gov/advisory-committees/human-drug-advisory-committees/pharmacy-compounding-advisory-committee
- World Anti-Doping Agency. The Prohibited List — S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics (2026). https://www.wada-ama.org/en/prohibited-list
Written By
Editorial team. We cite published research; we are not licensed clinicians and content is not medically reviewed.
Medical Disclaimer
The information on this website is for educational purposes only and is not medical advice. The content creators are not doctors or medical professionals. This content should not be used to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare provider before starting any new supplement, medication, or health protocol. You assume all risks associated with using this information.